D. Moertl (1, 2), R. Berger (1), A. Hammer (3), R. Hutuleac (1), R. Koppensteiner (3), C. W. Kopp (3), S. Steiner (3)
(1) Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria; (2) Department of Internal Medicine III (Cardiology), Landesklinikum St. Poelten, St. Poelten, Austria; (3) Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
fatty acids, inflammation, Heart failure, Platelets, Tissue factor
Chronic heart failure (CHF) is characterised by activation of neuroendocrine and inflammatory pathways, and both are linked to a prothrombotic state. Treatment with omega-3 polyunsaturated fatty acids (n3-PUFA) showed significant benefits including mortality reduction in CHF, but exact mechanisms of action are still unclear. We investigated the effects of n3-PUFA on markers of platelet activation and thrombogenesis in patients with severe CHF. Thirty-six patients with non-ischaemic CHF (LVEF<35%, NYHA class>2) under optimised therapy were randomised to supplementation with 1g/day or 4g/day n3-PUFA, or placebo for 12 weeks. Using whole-blood flow cytometry, monocyte-platelet aggregates characterised by CD14+/CD42b+ co-expression and monocytic tissue factor (TF) were determined. Plasma levels of P-selectin, sCD40L, fibrinogen, prothrombin fragment F1.2, TF and pro-inflammatory markers (high sensitive[hs] interleukin-6, hsCRP, hsTNF-alpha, monocyte chemotactic protein-1) were measured by immunoassay. Supplementation with 1g/day and 4g/day n3-PUFA but not placebo significantly reduced monocyte-platelet aggregates in a dose-dependent manner (p for trend=0.02 across the groups). A dose of 4g/day but not 1g/day n3-PUFA significantly decreased P-selectin (p=0.03). Plasma TF decreased dose-dependently upon n3-PUFA supplementation (p for trend=0.02), paralleled by a significant decrease of TF+-monocytes (p for trend=0.01). The amount of 4g/day n3-PUFA exhibited modest anti-inflammatory effects with a significant reduction of hs interleukin-6 (p<0.01) and a trend-wise reduction of hsTNF-alpha (p=0.09). No changes were seen for sCD40L, fibrinogen, hsCRP and monocyte chemotactic protein-1, while F1.2 was decreased by 4g/day n3-PUFA (P=0.03). In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF. Higher dosage exhibits also anti-inflammatory effects.
Hämostaseologie 2007 27 1: 55-58
Irene Lopez-Vilchez1, Gines Escolar1, Maribel Diaz-Ricart1, Berta Fuste1, Ana M. Galan1, James G. White2
Thromb Haemost 2007 97 2: 202-211
Gregor Hron1, Marietta Kollars1, Heinz Weber1, Verena Sagaster1, Peter Quehenberger2, Sabine Eichinger1, Paul A. Kyrle1, Ansgar Weltermann1
Thromb Haemost 2007 97 1: 119-123
The article “Feasibility and cost effectiveness of stroke prevention through community screening...
The April 2014 TH 111.4 issue of Thrombosis and Haemostasis is a Theme Issue by Guest Editor B....
Women with atrial fibrillation have a much higher risk for thromboembolic stroke than men suffering...